This program aims to develop CD47 × PD-L1 dual-targeted therapeutic fusion protein for immuno-oncology.
Rationale when developing the program:
In summary, combining therapy involves CD47 and PD-L1 may highlight a new outlook in cancer immunotherapy.
The programmed death-ligand 1 (PD-L1; or CD274, B7-H1) is a key anti-phagocytic signal, i.e "don't find me" signal, to the adaptive immune system. Similarly, CD47 is the key "don't eat me" signal for the innate immune system and adaptive immune response regulators. Both CD47 and PD-L1 are overexpressed on the surface of cancer cells. This can up-regulate the expression of their own regulators, therefore escaping immune surveillance.
Recent studies have shown that:
Here are some published data about CD47 × PD-L1 serving as a potential target for cancer immunotherapy.
(Liu, 2018)
We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop CD47 × PD-L1 Dual-Targeted Fusion Protein program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners further their programs with more chance to succeed. Look forward to cooperating with you in the near future.
For Research Use Only | Not For Clinical Use